Loading
ANBL0531 showed that children with intermediate-risk neuroblastoma can be cured almost every time with a treatment plan that gives less chemotherapy to those with favourable tumour biology and a good early response, keeping three-year survival at 95 percent while cutting treatment for many.
ANBL0531 was the Children's Oncology Group phase 3 study for intermediate-risk neuroblastoma, enrolling 464 patients (404 evaluable) between 2007 and 2011. Treatment intensity was assigned by tumour biology (histology, MYCN, ploidy, 1p and 11q status) and response, with two to eight cycles of carboplatin, etoposide, cyclophosphamide and doxorubicin, surgery when resectable, isotretinoin for the highest-risk subset, and observation alone for some infants with stage 4S disease. The primary endpoint was three-year overall survival.
Three-year event-free and overall survival were 83.2 and 94.9 percent, with overall survival of 100 percent for localised disease, despite reduced treatment for many subsets compared with earlier studies; the registry results give three-year overall survival of 99.4 percent in the lowest-intensity group and 88.4 percent in the highest. Infants with stage 4 disease and unfavourable biology did worse (three-year event-free survival 66.8 against 86.9 percent). The corpus's intermediate-risk neuroblastoma page cites ANBL0531 with A3961 for chemotherapy tailored by biology and response.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
464 enrolled.
95% CI 92.7 to 97.2
Source95% CI 79.4 to 87.0
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival at 3 years, all evaluable patientsprimary | Response- and biology-based therapy | 404 | 94.9% | - | - | link |
| Event-free survival at 3 years, all evaluable patients | Response- and biology-based therapy | 404 | 83.2% | - | - | link |
| Event-free survival at 3 years, infants with stage 4 disease by biology | Favourable biology | 61 | 86.9% | - | 0.02 | link |
| One or more unfavourable biological features | 47 | 66.8% | ||||
| Overall survival at 3 years by treatment group (registry results)primary | Group 2 (two cycles, surgery) | - | 99.4% | - | - | link |
| Group 3 (four cycles, surgery) | - | 93.5% | ||||
| Group 4 (eight cycles, surgery, isotretinoin) | - | 88.4% |
Shares Topotecan, Childhood cancers (all types), Children's Oncology Group (COG), Neuroblastoma (paediatric) and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Etoposide, Cyclophosphamide and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Etoposide, Doxorubicin and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Etoposide, Doxorubicin and the tag soc-trials.
Shares Childhood cancers (all types), Etoposide, Doxorubicin, Cyclophosphamide and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Etoposide, Cyclophosphamide and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Etoposide, Carboplatin and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Etoposide, Carboplatin and the tag soc-trials.